BioMarin signs license deal with GC Biopharma and Hanmi Pharm for Fabry disease therapy

BioMarin Pharmaceutical entered a license agreement with GC Biopharma and Hanmi Pharm to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease. BioMarin will pay $70M up front, with partners eligible for up to $405M in milestones.

Detected & updated continuously · Source: Nebula